Lannett Obtains FDA Approval For Phentermine Hydrochloride Capsules

7 Stocks You Need To Know For Tomorrow -- Free Newsletter

(RTTNews) - Pharmaceutical company Lannett Co. Inc. (LCI | charts | news | PowerRating) on Wednesday said it got the U.S. Food and Drug Administration or FDA approval for the company's supplemental Abbreviated New Drug Application or ANDA of Phentermine Hydrochloride Capsules 30 mg. The company expects to commence marketing of the product immediately.

The Philadelphia, Pennsylvania-based Lannett stated that Phentermine Hydrochloride or HCl is indicated for the short-term management of obesity. According to Wolters Kluwer, sales of generic Phentermine HCI Capsules exceeded $37 million for the 12 months ended October 2007.

Arthur Bedrosian, president and chief executive officer of Lannett commented, "This approval complements our Phentermine HCI Tablet 37.5 mg which is the generic equivalent of Adipex-P, marketed by Gate Pharmaceuticals, a division of Teva Pharmaceutical Industries, and is an important addition to our product portfolio."

LCI closed Wednesday's regular trading at $3.55, up $0.20 or 5.97%, on a volume of 20 thousand shares.

For comments and feedback: contact editorial@rttnews.com Copyright(c) 2007 RealTimeTraders.com, Inc. All Rights Reserved

Morning Coffee with TradingMarkets -- Free Newsletter

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index